Acquisition by Stephen Wargacki of 135000 shares of Aquestive Therapeutics subject to Rule 16b-3
| AQST Stock | USD 3.82 0.07 1.80% |
Slightly above 66% of Aquestive Therapeutics' investor base is looking to short. The analysis of overall sentiment of trading Aquestive Therapeutics stock suggests that many investors are alarmed at this time. Aquestive Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Aquestive Therapeutics' earnings reports, geopolitical events, and overall market trends.
Aquestive |
Filed transaction by Aquestive Therapeutics Executive. Grant, award or other acquisition pursuant to Rule 16b-3(d)
Read at macroaxis.com
Cash Flow Correlation
Aquestive Therapeutics' cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Aquestive Therapeutics' relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.Click cells to compare fundamentals
Aquestive Therapeutics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Aquestive Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Aquestive Therapeutics Fundamental Analysis
We analyze Aquestive Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Aquestive Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Aquestive Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Total Asset
Total Asset Comparative Analysis
Aquestive Therapeutics is currently under evaluation in total asset category among its peers. Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
Aquestive Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Aquestive Therapeutics stock to make a market-neutral strategy. Peer analysis of Aquestive Therapeutics could also be used in its relative valuation, which is a method of valuing Aquestive Therapeutics by comparing valuation metrics with similar companies.
Peers
Aquestive Therapeutics Related Equities
| ORGO | Organogenesis Holdings | 5.14 | ||||
| ANIP | ANI Pharmaceuticals | 1.95 | ||||
| LFCR | Lifecore Biomedical | 1.53 | ||||
| DVAX | Dynavax Technologies | 0.08 | ||||
| AMPH | Amphastar | 0.43 | ||||
| LNTH | Lantheus Holdings | 1.73 | ||||
| ALKS | Alkermes Plc | 2.27 | ||||
| SHPH | Shuttle Pharmaceuticals | 3.85 | ||||
| EVOK | Evoke Pharma | 4.45 | ||||
| IRWD | Ironwood Pharmaceuticals | 6.53 |
Additional Tools for Aquestive Stock Analysis
When running Aquestive Therapeutics' price analysis, check to measure Aquestive Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aquestive Therapeutics is operating at the current time. Most of Aquestive Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aquestive Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aquestive Therapeutics' price. Additionally, you may evaluate how the addition of Aquestive Therapeutics to your portfolios can decrease your overall portfolio volatility.